HLS Therapeutics Q1 Earnings Call Highlights

HLS Therapeutics TSE: HLS reported modest first-quarter revenue growth and reaffirmed its 2026 outlook, while management highlighted early momentum for the company's newly launched cholesterol drug NILEMDO and continued deleveraging of its balance sheet.